Overview

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study

Status:
Active, not recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES).

Phase:

Phase 4

Details

Lead Sponsor:

Kyoto University, Graduate School of Medicine

Treatments:

Aspirin
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists